LGS-4033 is an oral and nonsteroidal SARM (selective androgen receptor modulator, which binds to the androgen receptor with a high level of selectivity and affinity. It displays anabolic activities in the muscles, anabolic and anti-resorptive activities in the bones and a very strong selectivity for bone and muscle compared to sebaceous and prostate glands. LGC-4033 have been through various studies recently and also a lot of trials in order to establish the safest and best way to make use of it The results from these trials have demonstrated growth in the lean body mass and reduction in body fat.
It has been demonstrated that its use leads to a noticeable increase in well-being, strength and also has a lot of healing possibilities. Musch wasting, also involving a loss in skeletal muscle, is a symptom related to cancer which begins very early during the growth of cancer and impacts the patient’s quality of life, their ability to be able to tolerate chemotherapy and ultimately their survival.
SARMs help in increasing mass of the muscle and improve physical functioning in both healthy and individuals dealing with diseases, and this potentially may be able to provide a new way of therapy for cancer cachexia and muscle wasting. SARMs help in a modulation of the same anabolic pathways that are targeted by the classical steroidal androgens, though staying within the range of the dose where the effects expected on the mass of the muscle and functions are seen as androgenic side-effects on the skin, prostate, and hair has not yet been observed.
Studies conducted with anabolic agents like nandrolone for cachexia have demonstrated betterment in bone density and lean body mass, though some side effects like toxicity of liver and masculinization have occurred in women. Increase in lean mass and performance in muscle for HIV-infected men who have wasting disorders upon the testosterone treatments have also been observed. The all-encompassing effects on the prostate and heightening of the hematocrit still remain as drawbacks, though. A perfect SARM, like LGO-4033, which selectively grows the mass of the muscle and increases in hematocrit and decreases the effect of growth on the prostate, would make ab androgen treatment a much better option. Increase in muscle strength will surely result in decreased morbidity and mortality in cachectic people and may also allow patients in undergoing more intensive treatments like radiations.
Increasing bone formation and reducing bone loss are the two ways of protection against osteoporosis. In addition to vitamin 13 and calcium supplements, bisphosphonates are agents that are available for both women and men. These kinds of drugs enhance bone mineral density by blocking osteoclast activities. Hormone replacement therapy is also usually put to use for treating symptoms related to menopause but they are no longer being recommended for long-term treatment, because of risks of various complications. The use of SARMs in the treatment of osteoporosis will most likely benefit both women and men because they do not have the side-effects of virilization that are seen with steroidal androgens.
LGD-4033 was found to have a long elimination half-life and an accumulation that is dose-proportional upon multiple dosing(www.healthyheroics.com/lgd-4033-ligandrol-results-before-after). KCO-4033 was found to be safe and had a very favorable pharmacokinetic profile, and led to increased lean body mass without a change in antigen levels which are prostate-specific.